Patricia Boyle to Prostatic Hyperplasia
This is a "connection" page, showing publications Patricia Boyle has written about Prostatic Hyperplasia.
Connection Strength
1.094
-
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 2004 May; 45(5):620-6; discussion 626-7.
Score: 0.249
-
The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int. 2003 Nov; 92(7):719-25.
Score: 0.240
-
Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997 Jun; 49(6):839-45.
Score: 0.154
-
Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol. 1995 Mar; 153(3 Pt 1):669-73.
Score: 0.132
-
New insights into the epidemiology and natural history of benign prostatic hyperplasia. Prog Clin Biol Res. 1994; 386:3-18.
Score: 0.122
-
Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol. 1991; 20 Suppl 1:3-10.
Score: 0.099
-
Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003 Aug; 92(3):262-6.
Score: 0.059
-
Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998 Mar; 51(3):428-36.
Score: 0.041